ArticleAIDS (London, England)2025
The natural history of anal high-grade squamous intraepithelial lesions among MSM and transgender women in an acute HIV cohort in Thailand.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the incidence and clearance rates of anal high-grade squamous intraepithelial lesions (HSIL) among MSM and transgender women who initiated immediate antiretroviral therapy during acute HIV acquisition.
designA prospective cohort study of MSM and transgender women diagnosed with acute HIV acquisition in Bangkok, Thailand.
methodsParticipants who were enrolled from May 2017 to June 2020 underwent anal human papillomavirus (HPV) genotyping, high-resolution anoscopy, and anal biopsies as indicated, at baseline and 6-monthly follow-up visits.
resultsAmong 89 MSM and 4 transgender women (median age 26 years), the anal HSIL incidence rate was 22.7 per 100 person-years over 180.9 person-years, while the clearance rate was 119.4 per 100 person-years over 32.7 person-years. After adjusting for age, smoking, and baseline CD4 + cell count, incident anal HSIL was greater in those with persistent HPV 16 [adjusted hazards ratio (aHR) 14.98, 95% confidence interval (CI) 1.73-129.48], nonpersistent HPV 16 (aHR 15.12, 95% CI 1.84-124.50), persistent non-16 cancer-associated HPV types (aHR 17.90, 95% CI 2.34-136.74), and nonpersistent non-16 cancer-associated HPV types (aHR 10.65, 95% CI 1.34-84.93) compared to participants with consistently negative cancer-associated HPV. Persistent (aHR 0.17, 95% CI 0.04-0.66) and nonpersistent HPV 16 (aHR 0.22, 95% CI 0.05-0.98) were associated with lower HSIL clearance likelihood.
conclusionAmong predominantly young participants initiating antiretroviral therapy during acute HIV acquisition, anal HSIL showed high incidence yet markedly high clearance rates. Anal HPV 16 infection increased risk of incident anal HSIL and decreased lesion clearance. HPV vaccination and HSIL screening/treatment should be implemented despite rapid antiretroviral therapy initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.